Introduction {#Sec1}
============

In the past two decades, two outbreaks of coronaviruses (CoVs) in Asian subcontinent and the Middle East increased the chances of such outbreak in the near future. The severe acute respiratory syndrome coronavirus (SARS-CoV) outbreak at the end of 2002 (November) in China in which 8,098 confirmed cases were reported with 774 total deaths (9.6%) (Ksiazek *et al.*[@CR34]; WHO [@CR65]). Another coronavirus *i.e.* Middle East respiratory syndrome (MERS) occurred in 2012 with a fatality rate of around 35% (WHO [@CR62]; Bermingham *et al.*[@CR4]). Recently, a new coronavirus called as novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in December, 2019, in China. There is an emergence of global health threats and the situation became worse at the global level (Rodriguez-Morales *et al.*[@CR51]). The World Health Organization (WHO) termed the syndrome caused by the novel coronavirus as "COVID-19" on 11th, Feb 2020 (Gralinski and Menachery [@CR23]).

Coronaviruses fall in *Coronaviridae* family and subfamily *Coronavirinae*, the members of which infect a broad range of hosts, producing symptoms and diseases of wide spectrum from a flu like to severe acute respiratory infection (SARI). The SARS-CoV-2 is considered to be one of the seven members of the CoV family that infect humans (Zhu *et al.*[@CR72]). Similar to other coronaviruses, the transmission of SARS-CoV-2 among humans occurs through droplets, direct contact, any physical objects, and aerosols (WHO [@CR63]; Liu *et al.*[@CR38]). Owing to the rapid transmission, SARS-CoV-2 epidemic has become a global public health challenge. On March 11, COVID-19 outbreak was declared as a pandemic by WHO (Cucinotta and Vanelli [@CR12]). By June 10, more than 7 million people have been globally affected, with nearly 408,025 fatalities (WHO [@CR64]).

Due to the high morbidity and mortality rate of coronaviruses infection, there is an unmet need for therapeutic strategies to treat these diseases (Sarma *et al.*[@CR54]). Currently, there are no recommended therapeutic drugs or vaccine for coronaviruses. This emphasizes the surge for a suitable animal model to explore the pathogenesis and evaluation of countermeasures for the disease. With the outbreak of the coronaviruses, numerous animal models were developed in the past (Gralinski and Baric [@CR22]). The current review highlighted the animal models of coronaviruses, summarized the strength and weaknesses of the existing animal models along with their key features.

Animal Models for SARS-CoV-2 {#Sec2}
============================

Non-Human Primate Models {#Sec3}
------------------------

SARS-CoV-2 was recently recognized as a novel coronavirus causing the symptoms from mild to critical type (SARI). Munster *et al.* used SARS-CoV-2 infected rhesus macaques to study the pathogenesis of COVID-19. They observed high viral titers in nose swabs, throat swabs, and also lung lesions at varying degrees in all animals (Table [1](#Tab1){ref-type="table"}). This model recapitulates COVID-19 symptoms and can be used further to elucidate the therapy for SARS-CoV-2 infection (Munster *et al.*[@CR43]).Table 1Animal models of SARS-CoV-2.Sr. NoAnimal speciesDisease induction (strain and route)Clinical signsAdvantagesDisadvantagesReferences1Rhesus macaquesSARS-CoV-2, 2.6 × 10^6^ TCID~50~, IT or INVirus shedding in upper, lower respiratory tract and intestinal tractUseful for pathogenesis, vaccines and therapies studiesSmall sample sizeMunster *et al.* ([@CR43])2Rhesus macaques3--5 years old and 15 years old, SARS-CoV-2, 1 × 10^6^ TCID~50~, ITSevere interstitial pneumonia and significantly viral replication in respiratory tract in old monkeys than young monkeysUseful for pathogenesis, vaccines and therapies studiesClinical signs were transientYu *et al.* ([@CR69])3Rhesus macaquesSARS-CoV-2, 4.75 × 10^6^ PFU, IT and INIncreased body temperature, progressive pulmonary infiltration, high levels of viral genome RNA, showed progressively abnormal chest radiographSuitable for vaccines and therapeutics studies against SARS-CoV-2Availability, housing costLu *et al.* ([@CR39])4Macaca fascicularisSARS-CoV-2, 4.75 × 10^6^ PFU, IT and INProgressive pulmonary infiltration, abnormal chest radiograph; swab samples collected on 2 dpi from*M. fascicularis* showed surprisingly high levels of viral genomeMimic pathogenesis closer to clinical diseaseLower level of viral RNA, costly, limited size availabilityLu *et al.* ([@CR39])5Common marmosetSARS-CoV-2, 1.0 × 10^6^ PFU, IT and INOne-third of common marmoset had a slightly elevated body temperature, higher viral load in blood, lower levels of viral RNA were detected in swab samples from *C*. *jacchus*--Not showed severe histopathological changes in lung as pneumonia, relatively resistant to SARS-CoV-2 infectionLu *et al.* ([@CR39])6African green monkeysSARS-CoV-2, 5.0 × 10^5^ PFU, IT or INPulmonary consolidation with hemorrhage, pronounced viral pneumonia, release of inflammatory mediators with similar immune signatures as human casesConsidered gold standard model for infectious pathogensDid not develop overt, debilitating clinical illness; not easy to handle and costlyWoolsey *et al.* ([@CR66])7Cynomolgus monkeysSARS-CoV-2, 2 × 10^5^ TCID~50~, IT or INDiffuse alveolar damage in lungs and viral titer in upper and lower respiratory tractViral titer remain for long period and histopathological changes in the lungsNo overt clinical signsRockx *et al.* ([@CR50])8Transgenic hACE2 miceSARS-CoV-2 (HB-01), 10^5 ^TCID~50~/50 μL, INWeight loss and increase in virus replication in the lung and interstitial pneumonia also macrophages accumulation alveolar cavitiesFulfilled Koch\'s postulates; helpful in development of therapeutics and vaccinesShort supply and high cost of hACE2-transgenic mice; mild inflammatory responses and lung damageBao *et al.* ([@CR3])9BALB/c miceSARS-CoV-2 (MACSp6), 7.2 × 10^5^ PFU, INInfected all ages of mice; acute inflammatory responses closely related to the damage of lung tissues; levels of chemokines increased significantly in the aged mice as comparison to younger miceEasy handling breeding, convenient, economical, and effectively used for evaluation of *in vivo* evaluation of vaccines and therapeuticsExhibited moderate inflammatory responsesGu *et al.* ([@CR25])10BALB/c mice10-week old and 12 month-old SARS-CoV-2 MA, 10^5^ PFU, INAge-related increase in pathogenesisUseful for pathogenesis, vaccine immunogenicity and therapeutic efficacy studies--Dinnon *et al.* ([@CR16])11Transgenic hACE2 mice HFH4-hACE2 in C3B6 mice)SARS-CoV-2, 3 × 10^4^ TCID~50~ (for naïve infection) or 7 × 10^5^ TCID~50~ (for the viral challenge), INWeight loss, interstitial pneumonia, lymphopenia, gender susceptibility, viral titer in eye, heart & brain apart from lungsPartially simulated COVID-19 pathologyLD50 of the model is not determined; lethal encephalitisJiang *et al.* ([@CR31])12hACE2 miceSARS-CoV-2 4 × 10^5^ PFU-IN, 4 × 10^6^ PFU-IGHigh viral titre in lung, brain and trachea; interstitial pneumonia; increase cytokines levelsHelpful in study of transmission, pathogenesis, evaluating of vaccines and therapeutic efficacy-Sun *et al.*[@CR76]13Ad5-hACE2-transduced miceSARS-CoV-2 1 × 10^5^ PFU-INWeight loss, high virus titer in lungs, severe pulmonary pathologyUseful for the study of pathogenesis and testing for antiviral therapeutics and vaccinesAbsence of critical condition and extra-pulmonary manifestations of infectionSun *et al.*[@CR75]14HACE2-transduced miceSARS-CoV-2 1 × 10^5^ FFU- IN & IVWeight loss, high viral loads in lung, severe lung pathologyHelpful to study pathogenesis, vaccines and therapeuticsMouse to mouse variation in expression of hACE2, tissue distribution and mild bronchialHassan *et al.*[@CR74]15Golden Syrian hamsterSARS-CoV-2, 10^5^--10^7^ TCID~50~, INRapid breathing, loss of weight, diffuse alveolar damage and high lung viral load was observedReadily available, physiological, and highly similarity with COVID-19 useful for study of pathogenesis, therapeutics and vaccinesThere was a different outcomes in this study as comparison to previous study of SARS-CoV, not tested protein expression only tested mRNA of the hamsters cytokine profilesChan *et al.* ([@CR5])16Golden Syrian hamsterSARS-CoV-2, Beta-CoV/Hong Kong/VM20001061/2020 virus, 8 × 10^4^ TCID~50~, INWeight loss, significant viral replication, transmission of infection via aerosolsUseful for immunological studies for vaccine developmentRapid viral clearance on 7 dpiSia *et al.* ([@CR55])17FerretsSARS-CoV-2, 10^5.5^ TCID~50~, INShowed increased body temperatures and high virus titers in upper respiratory tractsViral infection and transmissionLow viral titer in lungsKim *et al.* ([@CR33])SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IN, intranasal; IT, intratracheal; IG, intragastric; TCID~50~, 50% Median Tissue Culture Infectious Dose; PFU, Plaque forming units; dpi, day post infection

Rockx *et al.* compared the pathogenesis of SARS and MERS with COVID-19 by inoculating cynomolgus macaques with virus infection (Rockx *et al.*[@CR50]). The virus samples were taken from the throat and nose. The diffuse alveolar damage was reported. The results of the study thus demonstrated that the infection with SARS-CoV-2 in non-human primates induced signs that resemble COVID-19 like disease, and the severity of virus infection lies in between the MERS and SARS (Mahase [@CR40]).

Yu *et al.* studied the association of virus infection with age. The viral strain was inoculated in rhesus macaques of 3--5 years old and 15 years old through intra-tracheal route. The clinical signs, for instance, viral replication, and histopathological changes were analyzed. Replication of virus was more in lungs and nasopharyngeal swabs of old rhesus macaque as compared to young rhesus macaque after infection. Old rhesus macaques also observed to have diffuse severe interstitial pneumonia (Yu *et al.*[@CR69]).

In a comparative study, three species of non-human primates were infected with SARS-CoV-2 (rhesus macaque, Macaca fascicularis, and common marmoset). Severe gross lesions and histopathological changes in the vital organs of all animals were observed. The study found that the rhesus macaque model was more susceptible to SARS-CoV-2, as compared to *Macaca* *fascicularis* and common marmoset (Lu *et al.*[@CR39]).

Woolsey *et al.* determined that African green monkeys supported a high level of SARS-CoV-2 replication and developed a respiratory tract related illnesses that might be more substantial than reported for other non-human primate species like cynomolgus and rhesus macaques. The study also reported high viral loads in feces and in mucosal samples of all monkeys after 15 days post-infection (dpi) (Woolsey *et al.*[@CR66]) (Table [1](#Tab1){ref-type="table"}).

Mouse Models {#Sec4}
------------

The inoculation of BALB/c mice with mouse-adapted SARS-CoV-2 at passage 6 (MACSp6) significantly affected all groups of mice irrespective of their ages. The infection resulted in moderate pneumonia and inflammation. A study reported higher viral load in lungs along with significant histopathological changes like denatured trachea, inflammation in pulmonary alveoli, detection of viral antigen in the trachea, bronchiole, in type II pneumocytes. There was a significant elevation of inflammatory chemokine and cytokines in sera and lung macrophages similar to clinical symptoms (Gu *et al.*[@CR25]).

Dinnon *et al.* constructed a recombinant virus (SARS-CoV-2 MA) that could replicate in both upper as well as lower airways of all groups of BALB/c mice irrespective of their ages. The results showed that there was more severe infection in aged mice in comparison to young mice (Dinnon *et al.*[@CR16]).

A study has been done based on the human ACE2 (hACE2) transgenic mice to investigate the pathogenesis of COVID-19. Infected mice reported weight loss and increased viral titer in lungs, and histopathological changes revealed the presence of interstitial pneumonia. The mice model seems to be promising for the evaluation of therapeutic measures for COVID-19 (Bao *et al.*[@CR3]).

One of the studies examined the infectivity and pathological changes in SARS-CoV-2 infected transgenic hACE2 mice, which was developed using lung ciliated epithelial cell-specific HFH4/FOXJ1 promoter 81. The model showed a partial simulation of the human COVID-19. The significant decrease in body weight, interstitial pneumonia, and fatality along with the involvement of other organs like heart, brain, and eye depicted its similarity to the human counterpart. The study also showed protection on reinfection in the survived mice (Jiang *et al.*[@CR31]) (Table [1](#Tab1){ref-type="table"}).

Sun SH *et al*. developed the hACE2 mouse model using CRISPR/Cas9 knock in technology to study the SARS-CoV-2 infection and compared it with the wild type C57BL/6 mice model. There was high viral titer in brain, lungs and trachea of hACE2 mice than wild type mice. SARS-CoV-2 infection in hACE2 mice associated with increased cytokine levels and interstitial pneumonia with no mortality. Moreover, intragastric inoculation of the SARS-CoV-2 infection altered significant pathological changes in lungs when compared to wild type mice (Sun *et al.*[@CR76]).

Sun J *et al.* developed a transgenic mice model by delivery of human ACE2 exogenously with a replication deficient adenovirus (Ad5-hACE2). The inoculation of mice with SARS-CoV-2 infection linked to high viral load in lungs along with weight loss and pneumonia. The role of type-1 interferon, signal transducer and activator of transcription 1 (STAT1) signaling is vital in viral clearance of virus and infection. Further, the study concluded the beneficial role of using human convalescent plasma and two antiviral agents (polyinosinic: polycytidylic acid and Remdesivir) (Sun J*et al.*[@CR75]).

Hassan *et al.* developed hACE2 transduced mice and infected these mice with SARS-CoV-2. The study observed significant weight loss, high viral load in lungs and severe lung pathology in infected mice (Hassan *et al.*[@CR74]).

Hamster Model {#Sec5}
-------------

Chan *et al.* observed significant binding of the novel coronavirus spike with the ACE2 receptor of the Syrian Hamster by *in silico* study (Table [1](#Tab1){ref-type="table"}). The viral load significantly increased in the hamster which leads to diffuse alveolar damage in the initial stage and extensive apoptosis in the later phase of infection (Chan *et al.*[@CR5]).

The clinical and histopathological observations from SARS-CoV-2 hamster model closely resemble to the clinical condition. The airway involvement is evident from nasal turbinate to the trachea and pulmonary alveoli, associated with changes of inflammation, cellular viral N protein expression, and high viral load during the first week. The disease progressed with increasing respiratory rate, decreasing activity, and progressive weight loss, and was found to be most severe by 6 dpi, which is similar to the disease course of COVID-19 patients (Huang *et al.*[@CR28]).

Sia *et al.* evaluated the transmission and pathogenesis of SARS-CoV-2 infection in the golden Syrian hamster model. The animal groups infected with SARS-CoV-2 showed significant weight loss, and viral replication in the respiratory tract. Viral load was high on 2 dpi and rapid clearance was observed on 7 dpi, which could be attributed to the presence of CD3 positive T-lymphocytes. The involvement of olfactory sensory neurons simulates the anosmia in COVID-19 cases. The transmission of SARS-CoV-2 to naïve hamsters by aerosols can be helpful for further studies (Sia *et al.*[@CR55]) (Table [1](#Tab1){ref-type="table"}).

Ferrets Model {#Sec6}
-------------

Kim *et al.* used ferrets to study the SARS-CoV-2 infection and its transmission. The study reported that the ferrets were more susceptible to infection and transmission of the virus from one ferret to naive ferrets by direct or indirect physical contact. They showed that infected ferrets exhibited more replication of the virus in the upper respiratory tract and it recapitulates COVID-19 human conditions and can be further used to evaluate the countermeasures for the disease (Kim *et al.*[@CR33]) (Table [1](#Tab1){ref-type="table"}).

Animal Models for SARS-CoV {#Sec7}
==========================

Non-Human Primate Models {#Sec8}
------------------------

For the development of SARS-CoV infection model, many species, like old and new world primates, were used. There was significant infection observed in cynomolgus (Fouchier *et al.*[@CR19]) and rhesus macaques (Rowe *et al.*[@CR52]), common marmosets (Greenough *et al.*[@CR24]) and African green monkeys (McAuliffe *et al.*[@CR42]), when the virus was inoculated within respiratory tract in those primates. However, in the case of squirrel monkeys and mustached tamarins, investigators were not able to induce infection (Roberts *et al.*[@CR48]; Subbarao and Roberts [@CR57]).

There was significantly high viral replication in cynomolgus, rhesus, and African green monkeys (McAuliffe *et al.*[@CR42]). While in marmosets, diarrhea, pneumonitis, fever, watery stool, and hepatitis were observed (Greenough *et al.*[@CR24]). Investigators have variable findings as a number of factors may affect the results, including age and animal source, dose, route of administration of infection and inoculation of the virus, and their history of the environment (Subbarao and Roberts [@CR57])*.*

However, results in out-bred species are not consistent because of biological variability. Therefore, it is important to carry large sample sizes for the study to find out the meaningful conclusions (Table [2](#Tab2){ref-type="table"}).Table 2Animal models of SARS-CoV.Sr. NoAnimal modelDisease induction (strain & route)Clinical signsAdvantagesDisadvantagesReferences1Rhesus macaquesSARS-CoV, Tor2, 10^7^ PFU, IV/ITSignificant viral titer in the lungsUseful for therapeutic evaluation and vaccines immunogenicityIn SARS study limited useRowe *et al.* ([@CR52])2Rhesus macaquesSARS-CoV, Urbani, 10^6^ PFU, IT/ INCould not show any clinical signUsed for Therapeutic evaluation and vaccines immunogenicityClinical illness was not presentMcAuliffea *et al.* (2004)3Rhesus macaquesSARS-CoV, PUMC01, 10^5^ PFU, INPulmonary changes were observed on 5--60 dpi; All macaques reported fever 2--3 dpiImmunological and pathological similarity with clinical conditionThe symptoms are less severe as comparison of clinical scenarioQin *et al.* ([@CR46])4Cynomolgus monkeysSARS-CoV, 10^3^ and 10^6^ TCID~50~, IN/ITInterstitial pneumonia, alveolar macrophages and neutrophils, diffuse alveolar damageHelpful for the study of SARS pathogenesis and can be used for therapeutic and vaccine studiesAvailability and costFouchier *et al.* ([@CR19])5Cynomolgus monkeysSARS-CoV, 1 × 10^6^ TCID~50~, IT/ IN,Symptoms appeared as difficulty in respiration; more diffuse alveolar damage, type 2 pneumocyte hyperplasia and alveolar macrophages are present in alveolar luminaUseful for vaccine and therapeutic drug evaluationThere is issue with availability, housing cost; early clearance of virus and pneumonitis occurredKuiken *et al.* ([@CR35])6Cynomolgus monkeysSARS-CoV, Tor2, 10^7^ PFU, ITMild cough; a few scattered pleural adhesionsPresentation of critical diseaseSymptoms cleared quickly and animals becomes asymptomatic from 8 to 10 daysRowe *et al.* ([@CR52])7Cynomolgus monkeysSARS-CoV, Urbani, 3 × 10^6.3^ PFU, IB/ IN,Reported nasal congestion, mild respiration distress; animals become lethargic; pulmonary related diseaseHelpful in immunogenicity of vaccines and therapeutics studiesLack of apparent clinical illnessMcAuliffe *et al.* ([@CR42])8African green monkeySARS-CoV, Urbani, 10^6.3^ TCID~50~, IB /IN,Virologic data and histopathologic findings, focal interstitial pneumonitis was noticed in some African green monkeyUseful for evaluation of vaccine efficacy against infectionRapid clearance of virus and pneumonitis in African green monkeyMcAuliffe *et al.* ([@CR42])9MarmosetSARS-CoV, Urbani, 10^6^ PFU, ITMarmoset reported there is elevation of temperature, interstitial pneumonitis, multifocal lymphocytic hepatitis and diffuse interstitial colitisCan be used in Pathogenesis, therapeutics and vaccine efficacy studiesThis model is not able to explain the viral antigen/viral RNA within hepatic tissuesGreenough *et al.* ([@CR24])10BALB/c mice4--6 week aged SARS-CoV, Urbani,10^5^ TCID~50~, INHigh viral load in respiratory tractUseful for immunological studiesNo overt clinical sign was presentSubbarao *et al.* ([@CR56])11BALB/c mice12--14 month aged SARS-CoV, Urbani, 10^5^ TCID~50~, INOld aged mice observed significant loss of weight, mild dehydration and alveolar damage; Also reported intra-alveolar edema, perivascular infiltratesUseful for vaccine evaluationThere is need of further characterization and immune senescenceVogel *et al.* ([@CR61])12129SvEv /STAT 1-/- miceSARS-CoV, Tor2, 6 × 10^6^ PFU/30 µL, INViral replication, morbidity, mortality and pneumonitisSTAT 1-/- exhibited innate immunityDefect in innate immunityHogan *et al.* ([@CR26])13129SvEv /STAT 1-/- miceSARS-CoV, Urbani, 10^5^ PFU, INReported severity of disease in this study, high virus replication and severe pulmonary lesionsViral replication, histopathology similar to clinical conditionsLack of a normal innate immune did not enhance virus pathogenesisFrieman *et al.* ([@CR20])14C57BL/6 miceSARS-CoV, Urbani 1 × 10^4^ TCID~50~, INVirus infected the respiratory tract (bronchial and bronchiolar epithelium); failure to thrive and also observed infection reached to the brainUseful for immunological studiesFail to show clinical signs of diseaseGlass *et al.* ([@CR21])15Transgenic hACE2 miceSARS-CoV, PUMC01 10^5^ TCID~50~, INTransgenic mice showed severe lung damage, systemic inflammatory reactions, degeneration, and necrosis in many extra-pulmonary organsMore susceptible to infection as comparison to wild type mice, and more closely resemblance to human pathology of SARSTissue distribution was limited, decreased expression of hACE2 and lack of lethalityYang *et al.* ([@CR67])16Golden Syrian hamster5-week aged, SARS-CoV, Urbani, 10^3^TCID~50~, INIncreased viral replication in lungs, related interstitial pneumonitis, diffuse alveolar damageReproducibility, increased viral replication in lungs which makes it suitable for immunoprophylaxis and immunotherapy and vaccines studiesAs virus is cleared rapidly from 7 to 10 dpi, there was no overt clinical illnessRoberts *et al.* ([@CR49])17Ferret and domestic catSARS-CoV, 10^6^ TCID~50~, ITLethargy and mortality in ferrets; histopathological changes including pulmonary consolidation was reported in both animalsUseful for vaccines, immunotherapy and therapeutic studiesAvailability; vulnerability to other respiratory virusesMartina *et al.* ([@CR41])SARS, Severe acute respiratory syndrome; IN, intranasal inoculation; IT, intratracheal inoculation; IV, intravenous inoculation; IB, intrabronchial inoculation; TCID~50~, 50% Median Tissue Culture Infectious Dose; PFU, Plaque forming units.

Mouse Models {#Sec9}
------------

There were different mice models used for the study of infection. When BALB/c mice were infected intranasally, there was an increase in viral titer in the lungs but no sign of morbidity or mortality was noticed. After 2 to 3 dpi, virus replication significantly increased in the respiratory tract but started decreasing at day 5 dpi (Subbarao *et al.*[@CR56]). This showed that young BALB/c mice failed to exhibit clinical signs of disease but permitted viral replication. On the other hand, a study showed that one-year-old BALB/c mice exhibited critical infection as compared to younger mice after SARS-CoV infection (Vogel *et al.*[@CR61]). Histopathological findings such as bronchiolitis, diffuse alveolar damage, and patchy interstitial pneumonitis were observed in BALB/c mice model of SARS-CoV. It was also observed that old age BALB/C mice were more prone to this disease as similar to the clinical symptoms observed in elderly people in the 2003 SARS outbreak.

One of the studies suggested that 129S mice infected with SARS-CoV exhibited virus replication and self-limited bronchiolitis. 129S mice strain also reported mild weight loss and pneumonitis after SARS-CoV infection. While on the other side, STAT 1 -/- mice in the 129S background observed sustained replication of the virus and histopathological changes, which were mimicking the human's disease. However, vaccine studies are limited where targeted mice have immune defects (Hogan *et al.*[@CR26]; Frieman *et al.*[@CR20]).

Moreover, C57BL/6 mice were also used as a SARS-CoV model. Virus isolates administered intranasal into C57BL/6 mice showed high replication in the respiratory tract of mice with a peak on the 3^rd^ day and clearance on the 9 dpi. The study observed the presence of transient systemic infection in the lungs which ultimately affects the brain (Glass *et al.*[@CR21]) (Table [2](#Tab2){ref-type="table"}).

Hamster Model {#Sec10}
-------------

Another model used to study the SARS-CoV infection is a golden Syrian hamster. There was a significantly high titer of viruses in the lungs along with interstitial pneumonitis (Roberts *et al.*[@CR49]). Because of the clinical signs like pulmonary histopathology and high virus load, the hamster can be used as a model for the study of therapeutics, immunotherapy, and immunoprophylaxis. It was observed that viruses got cleared off by 7dpi. (Table [2](#Tab2){ref-type="table"}).

Ferrets and Domestic Cat Model {#Sec11}
------------------------------

Various studies showed that domestic cats and ferrets are prone to SARS-CoV infection because virus replication, as well as specific antibodies, were found in both the species. After indicating drowsiness and epiphysitis 16 to 21 dpi, ferrets died (Martina *et al.*[@CR41]). However, with domestic cats, no further study has been conducted. After the inoculation of infection via intranasal route, the replication of the virus in the lungs and histological changes like pneumonitis were reported (ter Meulen *et al.*[@CR59]) (Table [2](#Tab2){ref-type="table"}).

Animal Models of MERS-CoV {#Sec12}
=========================

There is a difference in the homology of human and small animals DPP4 molecules which is the main virus receptor of MERS-CoV. Therefore, mice, guinea pig, and ferrets are not usually permissive to the MERS-CoV (Cockrell *et al.*[@CR7]; Coleman *et al.*[@CR9]; de Wit *et al.*[@CR13], [@CR14]; Raj *et al.*[@CR47]). However, non-human primates, rabbits, pigs, and dromedary camels are naturally permissive for the virus.

Dromedary Camel Model {#Sec13}
---------------------

Adney *et al.* studied the pathology and transmission of MERS-CoV among dromedary camels. The animals displayed slight increases in body temperature and rhinorrhea. A large quantity of nasal shedding of the virus is suggestive of an animal-to-animal and animal-to-human transmission which may occur through droplets or direct contact. MERS-CoV mainly affects the upper respiratory tract and mimics mild clinical signs. Since in clinical settings, the disease shows severe pathology, so camel as a model to study therapeutics is not suitable (Adney *et al.*[@CR1]) (Table [3](#Tab3){ref-type="table"}).Table 3Animal models of MERS-CoV.Sr. NoAnimal modelDisease induction (strain and route)Clinical SignAdvantageDisadvantageReferences1Dromedary camelsHCoV-EMC/2012, 1 × 10^7^ TCID~50~, IN, IT, CONRhinorrhea; mild elevation in body temperature; nasal discharge; mild to moderate acute intraepithelial & sub-mucosal inflammationReservoir source of the MERS-CoVMild clinical symptomsAdney *et al.* ([@CR1])2AlpacasDromedary MERS-CoV Al-Hasa_KFU-HKU13/2013, 1 × 10^6^ TCID~50~, OronasalPositive deep nasal swab at 10 dpiAlpacas as a potential substitute for camelsSmall sample size; insufficient observation period of 21 days before rechallenge; mechanism not evaluated;Crameri *et al.* ([@CR11])3Rhesus macaqueHCoV-EMC/2012, 7 × 10^6^ TCID~50~, IT, IN, oral, and ocular routesVirus shedding via nose, transient LRT infectionSusceptible to infectionSmall sample size; transient model; no mortalityde Wit *et al.* ([@CR13], [@CR14])4Rhesus macaqueshCoV-EMC, 6.5 × 10^7^ TCID~50~, ITIncreased temperature on 1--2 dpi; multifocal mild-to-moderate interstitial pneumonia; types I and II pneumocytes and alveolar macrophages contain infectionSusceptible to infectionNo detectable virus titersYao *et al.* ([@CR68])5Rhesus monkeysicMERS-0, 5 × 10^6^ PFU, ITLung hyperdensity changes, minimal-to-mild interstitial pneumonia; transient, mild pulmonary pathologyHigh replication of icMERS-0Mild infectionCockrell *et al.* ([@CR6])6Rhesus macaques (immunosupressive)EMC/2012, 7 × 10^6^ TCID~50~, ocularHigh viral shedding; mild pulmonary pathologyImmunopathogenic componentUse of immunosuppressive drug is not clinically relevant; immunosuppressive group is not challenged;Prescott *et al.* ([@CR45])7Common MarmosetHCoV-EMC/2012, 4 × 10^6^ TCID~50~, IN, IT and ocularLoss of appetite; decreased levels of activity; progressive severe pneumonia; extensive lesions in the lungs; severe, partially lethal disease modelSevere; longer duration; high viral loads in lungs; high viral load both in lower respiratory tract and in bloodSmall sample size; lack of additional control animals; subjects euthanized before the disease course could resolveFalzarano *et al.* ([@CR17])8Common MarmosetMERS-CoV-Jordan-n3/2012, 5 × 10^7^ PFU, IT; MERS-CoV-EMC/2012, 5 × 10^7^ PFU, ITRespiratory rate increased; interstitial multifocal to coalescing moderate pneumonia--No systemic clinical symptoms; limited clinical signs;Johnson *et al.* ([@CR32])9Yorkshire Landrace pigsMERS-CoV, 1 × 10^7^ TCID~50~, INViral RNA detected till 7 dpiInexpensive and easy to obtainNo animal to animal transmissionVergara-Alert *et al.* ([@CR60])10New Zealand white rabbitsEMC/2012, 1 × 10^3^ TCID~50~, or 1 × 10^5^ TCID~50~, IVNo clinical sign even on exposure to re-infection;Inexpensive and easy to obtainStudied asymptomatic infection, non-lethal infections, transient dose-dependent pulmonary infection which is not associated with clinical symptomsHouser *et al.* ([@CR27])11Transgenic mice (Ad5-hDPP4)EMC-2012, 1 × 10^5^ PFU, INWeight loss, virus replication in respiratory tract, interstitial pneumoniaUseful in screening of therapeutics and vaccines efficacy; Efficient and rapid generation of the model within 2--3 weeks; can be used in genetically deficient miceLevel of expression, tissue distributionZhao *et al.* ([@CR71])12Trangenic C57BL/6 J mice(hCD26/DPP4) CAGG enhancer/promoter, intron sequence, human CD26 cDNA, and rabbit beta globin poly(A) signalEMC-2012, 1 × 10^6^ TCID~50~, INIncrease virus titers in lungs and brains; progressive pneumonia; characterized by extensive; significant mortalitySusceptible to the infectionSevere morbidity and mortality; hinders investigations of underlying mechanismAgrawal *et al.* ([@CR2])13Swiss Webstar mice (hDPP4) (VelociGene technology)MERS-CoV- Hu/Jordan-N3/2012, 2 × 10^5^ PFU, INMild--moderate peribronchiolar & alveolar inflammationRapid mouse model production; no prior transduction is required;No cerebral inflammationPascal *et al.* ([@CR44])14Trangenic C57BL/6 J mice(hDPP4 model) (hCD26/DPP4) CAGG enhancer/promoter, intron sequence, human CD26 cDNA, and rabbit beta globin poly(A) signalEMC-2012, 1 × 10^6^ TCID~50~, INPersistent inflammatory infiltrates in the lungs; focal infiltrates in brain & liverFully permissive to viral infectionSevere morbidity and mortality; hinders investigations of underlying mechanismTao *et al.* ([@CR58])15Transgenic C57BL/6 mouse (hDPP4) model (purified 5861 bp fragment generated from ApaL1 digestion of pCAGGS-hDPP4)HCoV-EMC/2012 strain, 1 × 10^4.3^ TCID~50~, INDecreased activity; significant weight loss; mortalityMimic severe MERS pathologyUnderlying mechanism; mechanism of lethal which was of aberrant inflammatory response was not studiedZhao *et al.* ([@CR70])16Transgenic C57BL/6 J mice (CRISPR--Cas9 gene editing (homozygous & heterozygous strain))HCoV-EMC/2012, Camel MERS, icMERS, MERS-0 at 5 × 10^5^ PFU, IN; MERS-15 at 5 × 10^6^ PFU, INMortality and haemorrhage at 6 dpi; 25%--30% weight loss; diffuse alveolar damage and severe respiratory disease; decreased pulmonary function as measured by plethysmographyNo confounding effects of CNS infection on mortalityUse of high viral loadCockrell *et al.* ([@CR8])17Transgenic C57BL/6 mice (hDPP4-KI mice, mouse Dpp4 exons 10--12 replaced with the human DPP4 codons)Plaque-purified MERS~MA~, 1 × 10^4^ to 1 × 10^6^ PFU, INDiffuse alveolar damage; innate immune responses to infection; leukocyte response to infectionModel does not require prior sensitizationPathological changes associated with species specific MERS~MA~ mutationLi *et al.* ([@CR36])18Transgenic C57BL/6 mouse (R26-hDPP4 mice, insert hDPP4 into the Rosa26 locus using CRISPR/Cas9)hCoV-EMC, 1.5 × 10^5^ PFU, INSevere ARDS; viral titer in CNSSpecificity of the infection in lungs & in CNSNot severe or lethalFan *et al.* ([@CR18])19Transgenic mice on a C57BL/6 background express hDPP4HCoV-EMC 2012 strain, 1 × 10^5^ TCID~50~, INViral titer in lungsAge related immunopathologyNo severe disease and lethal infection, no nasal and brain inflammation; mild infection;Iwata-Yoshikawa *et al.* ([@CR30])MERS, Middle east respiratory syndrome; IN, intranasal; IT, intratracheal; CON, Conjuctivital; TCID~50~, 50% Median Tissue Culture Infectious Dose; PFU, Plaque forming units; LRT, lower respiratory tract; ARDS, acute respiratory distress syndrome; CNS, central nervous system; dpi, day post infection.

Alpaca Model {#Sec14}
------------

MERS-CoV is classified under Biosafety Level 3 which poses difficulty in using camels for infection study. Alpaca, belonging to the *Camelidae* family, provides an alternative to camels. Crameri *et al.* used alpaca as a prospective substitute to a camel for MERS-CoV vaccine testing (Crameri *et al.*[@CR11]). On exposure to MERS-CoV, the study observed dissimilarity between the immune response of two species. However, the pathogenesis of infection in alpaca is unknown (Table [3](#Tab3){ref-type="table"}).

Non-Human Primate Models {#Sec15}
------------------------

de Wit *et al.* used rhesus macaques to develop the MERS model. There was high viral load of MERS-CoV in the lower respiratory tract. The viral strain mainly affected type I and II pneumocytes that formed the architecture of the alveolar space. Since high expression of MERS-CoV was present in the lungs, therefore, there was limited virus shedding. There was no viral replication in the kidney. The study concluded that renal failure in humans might be associated with hypoxia but not with viral dissemination. Due to its transitory nature, this model of rhesus macaques was not found to be exactly mimicking the critical clinical cases (de Wit *et al.*[@CR13]). Similarly, Yao *et al.* observed a mild increase in temperature in rhesus monkeys. There was no virus detected in the upper respiratory tract. Significant pneumonia was observed with no systemic dissemination of the virus. The study concluded only lower respiratory infection with no extra-pulmonary effect (Yao *et al.*[@CR68]).

Human exposure to MERS-CoV leads to severe respiratory disease which might result in fatality and it is not easy to attain the same fatality rate in non-human primate models. Cockrell *et al.* used an infectious clone of novel MERS-CoV (icMERS-0) to induce MERS in the rhesus macaque. The clone strain was found to have higher pathogenicity in comparison to its wild type. MERS-CoV peaked at 3 to 5 dpi and resolved to 30 dpi. The respiratory disease was found to be placid and brief which resolves by day 30 dpi. The model mimics only mild infection of MERS in humans (Cockrell *et al.*[@CR6]).

In most of the cases, fatality is associated with comorbidities in MERS affected patients (Hui *et al.*[@CR29]; Saad *et al.*[@CR53]) and severity is linked to the immunocompromised state. In order to study the immune response and disease severity, Prescott *et al.* used the immunosuppressive drugs to down-regulate the immunity of rhesus macaques. The immunosuppressive state was found to be associated with a high titer of MERS-CoV but not supported by the pathology. In lung tissues, inflammatory cells significantly decreased in immunocompromised animals when evaluated histopathologically. This, in turn, shows the effect of the immune status of an individual on the shedding of the viral load. This study depicted the importance of considering the immune response along with using therapy to control infection in clinical settings (Prescott *et al.*[@CR45]) (Table [3](#Tab3){ref-type="table"}).

Marmosets are more prone to MERS-CoV infection than the rhesus macaques and it might be suitable to screen therapeutic strategies for the disease in marmoset (Johnson *et al.*[@CR32]; Falzarano *et al.*[@CR17]). The study by Falzarano *et al.* displayed an increase in severity following exposure to MERS-CoV in marmoset than rhesus macaque. The titer was almost 1000 times greater in marmoset than in rhesus macaque. The infection persisted for a longer duration as compared in rhesus macaque and need euthanasia. In fact, there was a systemic dissemination of the virus. But there was no viral dissemination in the kidney. The study observed that the marmoset model recapitulates more closely to human MERS (Falzarano *et al.*[@CR17]).

Johnson *et al.* used two clones of MERS-CoV *i.e.* MERS-CoV-Jordan-n3/2012 and MERS-CoV-EMC/2012. The inoculation of MERS-CoV into common marmosets resulted in mild to moderate clinical presentation of the disease which might be due to the manipulations of the marmoset to a certain extent (Johnson *et al.*[@CR32]) (Table [3](#Tab3){ref-type="table"}).

Yorkshire Landrace Pig Model {#Sec16}
----------------------------

Pigs are naturally permissive to the MERS-CoV infection (de Wit *et al.*[@CR73]). Vergara-Alert *et al.* used HCoVEMC/2012 to infect Yorkshire Landrace pigs. The study observed no animal-to-animal transmission though RNA dissemination of the virus was significantly high. Thus, this model cannot be used to study therapeutic strategies as it does not depict the true clinical condition (Vergara-Alert *et al.*[@CR60]) (Table [3](#Tab3){ref-type="table"}).

New Zealand White Rabbit Model {#Sec17}
------------------------------

Houser *et al.* studied the effect of re-infection in the rabbits. The model supported the replication of MERS-CoV-EMC/2012 virus. The model displayed asymptomatic infection which is not associated with any significant clinical sign. The model is not suitable for preclinical screening of therapeutics or vaccines for MERS (Houser *et al.*[@CR27]) (Table [3](#Tab3){ref-type="table"}).

Mouse Models {#Sec18}
------------

Mice are easily available, cost-effective, easy to handle, and suitable for initial screening of drug therapies and vaccines. Since, mice are not susceptible to MERS-CoV infection (de Wit *et al.*[@CR14]; Coleman *et al.*[@CR9]), therefore Zhao *et al.* developed a mouse model for MERS using a recombinant adenovirus that expresses humanized dipeptidyl peptidase-4 (hDPP4) receptor (Zhao *et al.*[@CR71]). The study concluded significant weight loss and virus dissemination in the respiratory tract. Further interstitial pneumonia was observed in the mice. The transient hDPP4 expression, mild respiratory system involvement with no fatality are the drawbacks of the model (Zhao *et al.*[@CR71]).

Though the previous study used an adenovirus vector to develop the DPP4 receptor in mice vulnerable to MERS-CoV infection, it did not mimic more closely to the clinical conditions. Agrawal *et al.* used tissue-specific and inducible promoters, to derive humanized DPP4 transgenic mice. On exposure to MERS-CoV, the model showed high susceptibility to the virus (Agrawal *et al.*[@CR2]). Briefly, the transgenic model depicted progressive pneumonia with fatality.

Agrawal *et al.* developed a hCD26/DPP4 transgenic mice and the receptors were distributed throughout the body which was not physiologically relevant (Agrawal *et al.*[@CR2]). Pascal *et al.* used Veloci Gene technology to rapidly develop a new humanized model. The model showed active viral replication in the respiratory tract without cerebral infection (Pascal *et al.*[@CR44]). Tao *et al.* observed constant inflammatory infiltrates in both brain and lungs in humanized CD26 (hCD26)/DPP4 mice. The high viral titer was observed in the lungs and in the brain of mice on exposure to MERS-CoV infection. The pathological examination found gross and microscopic inflammation which was not restricted to lungs but a sign of systemic dissemination along with fatality in 4--6 dpi (Tao *et al.*[@CR58]).

Tao *et al.* showed acute severe infection which hampers the opportunity to fully understand the pathogenesis. Zhao *et al.* developed a mouse model that exhibits the codon-optimized- hDPP4 receptor which on exposure to viral strain showed severe disease pathology in lungs which further affected the brain and kidney. The severe infection and aberrant immune response lead to mortality. The exact mechanism of the severity of the disease model requires further evaluation (Zhao *et al.*[@CR70]).

Cockrell *et al.* used CRISPR--Cas9 technology to genetically alter a non-permissive host receptor. The model showed severe respiratory distress and fatality response to MERS-CoV. This was further supported by plethysmography that showed decreased pulmonary function which might be due to the inflammation in pneumocytes and airway epithelial cells. The viral titers were not detected in the brain thereby nullifying any confounding factors which could lead to fatality (Cockrell *et al.*[@CR8]).

Li *et al.* developed transgenic mice, and inoculated with mouse adapted MERS-CoV (MERS~MA~) viral strain which caused weight loss, infection in airway epithelia, pneumocytes, and macrophages. Though the model was rapid to develop, required no prior sensitization, the pathological changes were exclusively associated with the species-adapted mutations of the MERS~MA~ clone. This hinders the model to fully mimic clinical conditions (Li *et al.*[@CR36]).

Fan *et al.* used CRISPR/Cas9 gene-editing technology to develop a knock-in-model of mice. The study displayed a high level of expression of hDPP4 in the respiratory tract and to a lesser extent in the brain. There is a clear site of infection along with acute respiratory distress syndrome (ARDS) in the lungs. There is also the dissemination of viruses into the central nervous system (CNS). The study observed high repeatability and the safety of the model (Fan *et al.*[@CR18]).

Iwata-Yoshikawa *et al.* developed a transgenic mouse model using the endogenous promoter. The hDPP4 mice model showed a high viral titer in the lower respiratory tract. Acute multifocal interstitial pneumonia was observed at 7 dpi. The viral titer was also observed in peripheral blood and lymphoid tissues. There was an age-associated immune response to exposure to the viral strain. The model expressed mild infection pathology. Moreover, after the infection, this model had not shown any signs of lesions in the brain and kidney (Iwata-Yoshikawa *et al.*[@CR30]) (Table [3](#Tab3){ref-type="table"}).

Conclusions {#Sec19}
===========

The coronaviruses pathology is associated with the involvement of severe acute respiratory infection (SARI) and immune deregulation, thus, it is requisite to perform a study using an assay system that must involve all the cell signalling and thus, using animal model is an unparallel approach.There are some animal models that recapitulate mild to moderate pathology, however, the clinical condition is related to high mortality and morbidity. Therefore, animal models which mimic critical pathologies are much closer to clinical conditions.The novel coronavirus (COVID-19) pathology is linked to viral respiratory infection, hyper-immune response, and coagulopathy (Lin *et al.*[@CR37]; Connors and Levy [@CR10]), therefore, to understand the mechanism or to evaluate therapeutic countermeasures, the animal models should involve all these interplays in a single model. Since with the advent of technology, transgenic mice are the significant tool but the transgenic mice lack the coagulopathy component which is indispensable in order to understand the complete mechanism and to evaluate the countermeasures.Further, validation of the animal model is crucial. The error in the animal experimental study narrows the chances of the potential drugs or repurposing or repositioning drugs or vaccines to translate successfully to clinics and moreover, it is a wastage of resources. Thus, it is the need of the hour to validate the animal model using different criteria, for instance, face, construct, and predictive validity (Denayer *et al.*[@CR15]).
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